In addition, our study allows the identification of an immunosuppressive signature characterized by high GLI and low cytokine/chemokine expression (CCL7, CCL2, CCL20, CXCL8, CXCL1 and CXCL10), which could be used to stratify melanoma patients with poor survival. Here, CXCL10 is linked to melanoma.